Page 57 - கொலோன் பல்கலைக்கழகம் மருத்துவமனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Credit: NIAID Cologne, Marburg, Braunschweig and Ingelheim, Germany, 18 December 2020 - Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody. By combining UKK, UMR and DZIF s expertise in virology, immunology and clinical investigation with Boehringer Ingelheim s expertise in developing and manufacturing therapeutic antibodies, the partners developed BI 767551 as a potential new therapeutic and preventive/prophylactic option for fighting COVID-19. Virus neutralizing antibodies are expected to become an important line of defense against SARS-CoV-2, complementing vaccines and nonpharmaceutical interventions. They are being investigated as a therapy option for individuals with mild or severe infections, but also as prevention or prophylaxis in non-infected people with a high risk of

Rheinland pfalzFlorian kleinMichel pairetStephan beckerUniversity of marburgUniversity hospital of cologneBoehringer ingelheimInstitute of virology at university marburgGerman centerInfection researchAnimal healthInstitute for virologyCologne university hospitalUniversity hospitalPrincipal investigatorCoordinator emerging infections